Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Brexit: Medicine Supplies Face ‘Significant Disruption’ At Ports

Situation Worst In First Quarter Of 2021

Executive Summary

As negotiators struggle to reach agreement on the future UK/EU relationship, pharma firms have been warned to expect major hold-ups next year for medicines crossing the Channel. 

You may also be interested in...



Brexit: Companies Must ‘Act Now’ To Avoid Drug Supply Disruptions In 2021

In its latest letter to medicines and medical product companies, the UK's Department of Health and Social Care says the biggest potential cause of disruption to supplies could be failure to prepare for border controls implemented by the EU member states after the end of the Brexit transition period.

Brexit: UK Secures Ferry Space For Medicines To Circumvent Port Delays

New checks due to be imposed when the UK leaves the EU single market and customs union in 2021 are expected to cause widespread disruption to consignments of medicines and other vital goods at the Channel ports. The government says it has secured space on nine new ferry routes in an effort to help keep supplies going.

Gloom Over Prospects For Brexit Trade Deal

With time running out on the UK-EU trade deal negotiations, the UK life sciences industry looks at the fine print of the new guidance on medicines regulation and explains why a mutual recognition agreement is urgently needed. 

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS142766

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel